in vivo

ISSN (print): 0258-851X; ISSN (online): 1791-7549

International Journal of Experimental and Clinical Pathophysiology and Drug Research
Published bimonthly by the International Institute of Anticancer Research
Available online with Stanford University HighWire Press

General Policy
- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office
International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org
For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles
- Identification of Four Isoforms of Aldolase B Down-regulated in Hepatocellular Carcinoma Tissues by Means of Two-dimensional Western Blotting. Y. WANG, Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, I. SAKAIDA, M. OKA, K. NAKAMURA (Ube, Japan)
- Effects of Polo-like-kinase-1-inhibitor BI 2536 in Squamous Cell Carcinoma Cell lines of the Head and Neck- first In Vitro Results. J. WAGENBLAST, D. HIRTH, L. THRON, C. ARNOLDNER, M. DIENSTHUBER, T. STÖVER, M. HAMBEK (Frankfurt am Main, Germany; Vienna, Austria)
- Expression Patterns and Potential Action of the Calcium Transport Genes Trp5, Trp6, Ncx1 and Pmca1b in the Canine Duodenum, Kidney and Uterus. J.-A. KIM, H. YANG, I. HWANG, E.-M. JUNG, K.-C. CHOI, E.-B. JELING (Chungbuk, Republic of Korea)
- Post-operotive Corticosterone Levels in Plasma and Feces of Mice Subjected to Permanent Catheterization and Automated Blood Sampling. R. SUNDBOM, K.R. JACOBSEN, O. KALLIOKOSKI, J. HAU, K.S.P. ABELSON (Uppsala, Sweden; Copenhagen, Denmark)
- Repair of Postauricular Defects Using a New Technique: The Swallowtail Flap. C. MONARCA, M. MARUCCIA, F. PALUMBO, N. SCUDERI (Rome, Italy)
- Adipocyte-derived Factor as a Modulator of Oxidative Estrogen Metabolism: Implications for Obesity and Estrogen-dependent Breast Cancer. H.L. BRADLOW, D.W. SEPKOVIC, N. TELANG, R. TIWARI (New York, NY, USA)
- No Cytomegalovirus Detected in the Gastrointestinal Tract of Patients with Active Crohn’s Disease. M.T. AARNIO, J.P. ÖBRADLOW, D.W. SEPKOVIC, N. TELANG, R. TIWARI (New York, NY, USA)
- Colon Cancer Vaccines: An Update (Review). E. MERIKA, M.W. SAIF, A. KATZ, C. SYRIGOS, M. MORSE (London, UK; Haven, CT; Durham, NC, USA; Athens, Greece)
- Metastatic Potential of Orthotopic and Heterotopic Models Imaged by GFP and RFP Protein (Review). V. BOBEK, K. KOLOSTOVA, D. PINTEROVA, M. BOUBELIK, R. GURLICH, R.M. HOFFMAN (Prague, Czech Republic; San Diego, CA, USA)
- Serotonin Transporter Polymorphism in Major Depressive Disorder (MDD), Psychiatric Disorders, and in MDD in Response to Stressful Life Events: Causes and Treatment with Antidepressant (Review). A. DANIELE, R. DIVELLA, A. PARADISO, V. MATTIOLI, F. ROMITO, F. GIOTTA, P. CASAMASSIMA, M. QUARANTA (Bari, Italy)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedial research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Subscription Order Form 2012

☐ Please enter a Subscription to ANTICANCER RESEARCH for Volume 32 (2012).

Annual subscription rates (2012): Institutional, Euro 1,650.00 - online; 1,670.00 - print; 1,700.00 - print & online.
Personal, Euro 780.00 - online; 800.00 - print; 830.00 - print & online. Prices include rapid delivery and insurance.
2012 online subscriptions include free online access to vol. 24 (2004) - 31 (2011).

☐ Please send me the following previous volumes (1-31) at 50% discount on the above rates.

☐ Payment is enclosed. ☐ Please invoice.

(Cheques should be made payable to J.G. Delinassios, Athens, Greece)

☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ...........................................................................................................................................................................
Tel: ..............................................................................................................................................................................................
Fax: ..............................................................................................................................................................................................
e-mail: ......................................................................................................................................................................................
Signature: .................................................................................................................................................................................... Date: ..........................................................................................

Please send this order to ANTICANCER RESEARCH, Editorial Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti,
P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

Special 2012 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2012 on a basis of priority and availability.
Effective from January to December 2012).

Please complete and send this order form to:
ANTICANCER RESEARCH Editorial Office, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2012

☐ I am one of the authors of the article published in Anticancer Research Vol........, pp. ........, year .........

☐ Please enter my personal subscription to Anticancer Research 2012 (Volume 32) at the special Author’s rate of ☐ Euro 417.00 (print);
☐ Euro 217.00 (online); ☐ Euro 500.00 (print & online).

☐ Please send me previous Volume No(s) .......... at Euro 208.00 (print) per volume.

☐ Please enter my personal combined 2012 subscription to Anticancer Research (Volume 32), IN VIVO (Volume 26) and CANCER GENOMICS & PROTEOMICS (Volume 9) at ☐ Euro 655.00 (print); ☐ Euro 354.00 (online); ☐ Euro 824.00 (print & online).

☐ My payment is enclosed.

☐ Please send me an invoice.

(Prices include rapid delivery and insurance. Cheques should be made payable to J.G. Delinassios, Athens, Greece).

Name and address: ...................................................................................................................................................................
Tel-Fax: ......................................................................................................................................................................................
e-mail: ......................................................................................................................................................................................
Date and signature: ...................................................................................................................................................................
General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press: For more information please visit our websites www.cgp-journals.com; www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office
International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. e-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

KRAS Mutation is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma. T. WIEDL, S. COLLAUD, S. HILLINGER, S. ARNI, C. BURGESS, W. KROLL, P. SCHRAMEL, A. SOLTERMAN, H. MOCH, W. WEDER (Zurich, Switzerland; Cambridge, MA, USA)

Early detection of Ovarian Cancer in Pre-diagnosis Samples Using CA125 and MALDI MS Peaks. J.F. TIMMS et al (London; Reading, UK)

Decoding Differentially Regulated Epithelial and Stromal Pathways in Colorectal Cancer. M. ABBA, S. LAUFS, M. AGHAJANY, B. KORN, A. BENNER, H. ALLGAYER (Heidelberg, Germany)


Small Molecule Inhibition of Cytoskeletal Dynamics in Melanoma Tumors Results in Altered Transcriptional Expression Patterns of Key Genes Involved in Tumor Initiation and Progression. C. SPENCER, J. MONTALVO, S.R. MCLAUGHLIN, B.A. BRYAN (Worcester, MA, USA)

Gene Expression Profile Can Predict Pathological Response to Preoperative Chemoradiotherapy in Rectal Cancer. M. NISHIOKA, M. SHIMADA, N. KURITA, T. IWATA, S. MORIMOTO, K. YOSHIIKAWA, J. HIGASHIJIMA, T. MIYATA (Tokushima, Japan)

Gene Expression Profiling and its Utility in Prediction of Local Recurrence in Prostate Cancer. N. CERVERA, A. TALLET, M. BENCHALAL, G. HOUVENAESCHE, J. JACQUEMIER, D. BIRNBAUM, P. BERTUCCI (Marseille, France)

Restoration of Senescence in Breast and Ovarian Cancer Cells Following the Transfer of the YAC Carrying SEN6A Gene Located at 6q16.3. N.S. RANE, A.K. SANDHU, V.S. ZHAWAR, G. KAUR, N.C. POPESCU, R.P. KANDPAL, M. JHANWAR-UNIYAL, R.S. ATIHAL (Philadelphia, PA; Bethesda, MD; Pomona, CA; Valhalla, NY, USA)

Therapy- Gender- and Race- specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival. K.R. DELFINO, N.V.L. SERÃO, B.R. SOUTHEY, S.L. RODRIGUEZ-ZAS (Urbana, IL, USA)


The Cancer Biomarker Osteopontin: Combination with Other Markers (Review). G.F. WEBER (Cincinnati, OH, USA)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFIIE2 in Prostate Carcinoma (Review). T. RIBARKA, M. INGENWERTH, W. GOERING, W.A. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

TGF-β1 Interactome: Metastasis and Beyond (Review). M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEIJKAL, M.G. SMITH, A.J. TRACHITENBERG, W.P. KUO (Hong Kong, HK; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA)

Pathogenetic and Clinical Relevance of microRNAs in Colorectal Cancer (Review). N. VALERI, C.M. CROCE, M. FABBRI (Columbus, OH, USA; Ferrara; Meldola, Italy)

The Continuing Search for Predisposing Colorectal Cancer Variants (Review). S. PICELLI, S. VON HOLST, P. WESSENDORF (Stockholm, Sweden)
TRAIL and Taurodilin Enhance the Anticancer Activity of Doxorubicin, Trabectedin and Mafosfamide in HT1080 Human Fibrosarcoma Cells. K. HARATI, A.M. CHROMIK, D. BULUT, O. GOERTZ, S. HAHN, T. HIRSCH, L. KLEIN-HITPASS, M. LEHNHARDT, W. UHL, A. DAIGELER (Ludwigshafen; Bochum; Essen, Germany) .......................................................................................................................... 2967

Fiber-substituted Conditionally Replicating Adenovirus for Oncolysis of Human Renal Carcinoma Cells. H. NAGAYA, M. TAGAWA, K. HIWASA, S. TERAO, T. KANNO, T. NISHIZAKI, A. GOTOH (Nishinomiya, Hyogo; Chiba, Japan) .................................................................................................................................................................................................................. 2985

* Review: The Potential of RECK Inducers as Antitumor Agents for Glioma. Y. CHEN, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC) ........................................................................................................................................................................................................................................ 2991


LXR Agonists and ABCG1-dependent Cholesterol Efflux in MCF-7 Breast Cancer Cells: Relation to Proliferation and Apoptosis. A. EL ROZ, J.-M. BARD, J.-M. HUVELIN, H. NAZIH (Nantes; Saint Herblain, France) ........................................................................................................................................................................................................................................ 3007

* Reviews (pages 2391, 2423, 2439, 2463, 2471, 2487, 2515, 2567, 2585, 2591, 2599, 2747, 2755, 2783, 2935, 2947, 2991, 2999)
Effects of Docetaxel, Doxorubicin and Cyclophosphamide on Human Breast Cancer Cell Line MCF-7. M. TREBUNOVA, G. LAPUTKOVA, E. SLABA, K. LACJAKOVA, A. VEREBOVA (Kosice, Slovakia) 2849

Invasive Inhibition and Proapoptotic Activity Induction by the Rexinoid IIF and Valproic Acid in Combination on Colon Cancer Cell Lines. A. PAPI, A.M. FERRERI, F. GUERRA, M. ORLANDI (Bologna, Italy) 2855

In Vitro Cytotoxic Activity of Novel Protoflavone Analogs – Selectivity Towards a Multidrug Resistant Cancer Cell Line. B. DANKO, A. MARTINS, D.W. CHUANG, H.C. WANG, L. AMARAL, J. MOLNÁR, F.R. CHANG, Y.C. WU, A. HUNYADI (Szeged, Hungary; Kaohsiung; Taichung, Taiwan; ROC; Lisbon, Portugal) 2863

The Organic Arsenic Derivative GMZ27 Induces PML–RARα- Independent Apoptosis in Myeloid Leukemia Cells. X. CHENG, A. QUINTAS-CARDAMA, M. GOLEMOVIC, R. ZINGARO, M.-Z. GAO, E.J. FREIREICH, M. ANDREEFF, H.M. KANTARJIAN, S. VERSTOVSEK (Tampa, FL; Houston, College Station, TX; Indianapolis, IN, USA) 2871

Comparative Chemosensitivity of Circulating Human Prostate Cancer Cells and Primary Cancer Cells. R. MENEN, M. ZHAO, L. ZHANG, M.K. HASSANEIN, V. BOBEK, K. KOLOSTOVA, M. BOUVET, R.M. HOFFMAN (San Diego; Oakland, CA, USA; Prague, Czech Republic) 2881


(−)-Epicatechin Enhances Etoposide-induced Antileukaemic Effect in Rats with Acute Myeloid Leukaemia. M.A. PAPIEŻ, K. BUKOWSKA-STRAKOVΑ, W. KRZYŚCIAK, J. BARAN (Krakow, Poland) 2905

Cytotoxicity of Ruthenocene-containing β-Diketones. K.C. KEMP, M.J. NELL, C.E.J. VAN RENSBURG, J.C. SWARTS (Bloemfontein; Pretoria, Republic of South Africa) 2915

Novel Liposomal Gefitinib (L-GEF) Formulations. X. ZHOU, B. YUNG, Y. HUANG, H. LI, X. HU, G. XIANG, R.J. LEE (Wuhan, PR China; Columbus, OH, USA) 2919

Cytotoxicity and Type of Cell Death Induced by Local Anesthetics in Human Oral Normal and Tumor cells. K. KOBAYASHI, S. OHNO, S. UCHIDA, O. AMANO, H. SAKAGAMI, H. NAGASAKA (Saitama, Japan) 2925

* Review: New Molecularly Targeted Therapies for Glioblastoma Multiforme. J. POLIVKA JR., J. POLIVKA, V. ROHAN, O. TOPOLCAN, J. FERDA (Pilsen, Czech Republic) 2935

* Review: Inhibitors of Bacterial Efflux Pumps that also Inhibit Efflux Pumps of Cancer Cells. L. AMARAL, G. SPENGLER, A. MARTINS, A. ARMADA, J. HANDZLIK, K. KIEC-KONONOWICZ, J. MOLNÁR (Lisbon; Krakow, Portugal; Szeged, Hungary) 2947

Oxazolinodoxorubicin – a Promising New Anthracycline. M. LUKAWSKA, D. KLOPOTOWSKA, M. MILCZAREK, J. WIETRZYK, K. STUDZIAN, L. SZMIGIERO, A. POREBSKA, I. OSZCZAPOWICZ (Warsaw; Wroclaw; Lodz, Poland) 2959

Contents continued on the preceding page
Anticancer Effects of Eleven Triterpenoids Derived from Antrodia camphorata. Y.-P. LEE, W.-C. TSAI, C.-J. KO, Y.K. RAO, C.-R. YANG, D.-R. CHEN, M.-H. YANG, C.-C. YANG, Y.-M. TZENG (Taichung; Changhua; Chiayi, Taiwan, ROC) ................................................................. 2727

In Vitro and In Vivo Anticancer Effects of Destruxin B on Human Colorectal Cancer. Y.-P. LEE, C.-W. WANG, W.-C. LIAO, C.-R. YANG, C.-T. YEH, C.-H. TSAI, C.-C. YANG, Y.-M. TZENG (Taichung; Changhua; Chiayi; Taipei, Taiwan, ROC) .................................................. 2735

* Review: Role of Melatonin in Cancer Treatment. A. CUTANDO, A. LÓPEZ-VALVERDE, S. ARIAS-SANTIAGO, J. DE VICENTE, R. GÓMEZ DE DIEGO (Granada; Salamanca; Madrid, Spain) ......................................................... 2747

* Short Review: New Frontiers for Astrocytic Tumours. R. NANO, A. LASCIALFARI, M. CORTI, A. PAOLINI, F. PASI, F. CORBELLA, R. DI LIBERTO (Pavia; Milan, Italy) ................................................................. 2755


Combination of Three Metals for the Treatment of Cancer: Gallium, Rhenium and Platinum. 1. Determination of the Optimal Schedule of Treatment. P. COLLERY, A. MOHSEN, A. KERMAGORET, J. D’ANGELO, G. MORGANT, D. DESMAELE, A. TOMAS, T. COLLERY, M. WEI, A. BADAWI (Bastia; Chatenay-Malabry; Paris; Maisons Alfort, France; Cairo, Egypt) .......................................................... 2769

* Review: Mafosfamide as a New Anticancer Agent: Preclinical Investigations and Clinical Trials. L. MAZUR, M. OPYDO-CHANEK, M. STOJAK, K. WOJCIESZEK (Krakow, Poland) .................................................. 2783

Effect of Histone Deacetylase Inhibitors Trichostatin A and Valproic Acid on Etoposide-induced Apoptosis in Leukemia Cells. E. JASEK, G.J. LIS, M. JASIŃSKA, H. JURKOWSKA, J.A. LITWIN (Krakow, Poland) ............................................................. 2791

The Anticancer Effect of 2’-3’-dehydrosalannol on Triple-negative Breast Cancer Cells. T. BOOPALAN, A. ARUMUGAM, C. DAMODARAN, L. RAJKUMAR (El Paso, TX, USA) .......................................................... 2801

Efficacy of Combination Chemotherapy Using Oral Fluoropyrimidine S-1 with Oxaliplatin (SOX) against Colorectal Cancer In Vivo. M. NUKATSUKA, H. SAITO, K. SAKAMOTO, F. NAKAGAWA, J. UCHIDA, T. KOBUNAI, K. SHIRAISHI, T. TAKECHI (Tokushima; Ibaraki; Tokyo, Japan) ........................................... 2807

Effect of BMP4 on the Growth and Clonogenicity of Human Leukemia and Lymphoma Cells. Y. TAKAHASHI, T. ISHIGAKI, Y. OKUHASHI, A. ONO, M. ITOH, N. NARA, S. TOHDA (Tokyo, Japan) ......................................................... 2813

Relationship between Structure and Antiproliferative Activity of 1-Azaflavanones. S. KAWAI, K. ENDO, T. TOKIWANO, Y. YOSHIZAWA (Saitama; Akita, Japan) ............................................................. 2819


Contents continued on the preceding page

* Review: Tumor Cell-protective Catalase as a Novel Target for Rational Therapeutic Approaches Based on Specific Intercellular ROS Signaling. G. BAUER (Freiburg, Germany) ................................................................. 2599

The Root Bark of Paeonia moutan is a Potential Anticancer Agent in Human Oral Squamous Cell Carcinoma Cells. C. LI, K. YAZAWA, S. KONDO, Y. MUKUDAI, D. SATO, Y. KURIHARA, T. KAMATANI, S. SHINTANI (Tokyo, Japan; Jian, Jiangxi Province, PR China) .................................................................................................................. 2625

Protein-bound Polysaccharide-K (PSK) Induces Apoptosis via p38 Mitogen-activated Protein Kinase Pathway in Promyelomonocytic Leukemia HL-60 Cells. N. HIRAHARA, T. EDAMATSU, A. FUJIEDA, M. FUJIOKA, T. WADA, Y. TAJIMA (Izumo; Tokyo, Japan) ........................................................................................................... 2631

Synergistic Inhibition of HTLV-1-infected Cell Proliferation by Combination of Cepharanthine and a Tetramethylnaphthalene Derivative. M. TOYAMA, T. HAMASAKI, T. UTO, H. AYAMA, M. OKAMOTO, Y. HASHMOTO, M. BABA (Kagoshima; Tokyo, Japan) ........................................................................................................... 2639

Delta-tocotrienol Augments Cisplatin-induced Suppression of Non-small Cell Lung Cancer Cells via Inhibition of the Notch-1 Pathway. X. JI, Z. WANG, F.H. SARKAR, S.V. GUPTA (Detroit, MI, USA) ........................................................... 2647


Effects of (5Z)-7-Oxozeaenol on the Oxidative Pathway of Cancer Cells. U. MUÑOZ ACUÑA, J. WITTWER, S. AYERS, C.J. PEARCE, N.H. OBERLIES, M.J. CARCACHE DE BLANCO (Columbus, OH; Greensboro; Hillsborough, NC, USA) .................................................................................. 2665

Apoptotic Effects of Resveratrol, a Grape Polyphenol, on Imatinib-Sensitive and Resistant K562 Chronic Myeloid Leukemia Cells. G. CAN, Z. CAKIR, M. KARTAL, U. GUNIOZ, Y. BARAN (Urla, Izmir; Cankaya, Ankara, Turkey) .............................................................................................................................................. 2673

Enhancement of Cisplatin Cytotoxicity by Disulfiram Involves Activating Transcription Factor 3. A. O'BRIEN, J.E. BARBER, S. REID, N. NIKNEJAD, J. DIMITROULAKOS (Ottawa, ON, Canada) ................................................................. 2679

Effects of Zeng Sheng Ping/ACAPHA on Malignant Brain Tumor Growth and Notch Signaling. K.J. LIM, K. RAJAN, C.G. EBERHART (Baltimore, MD, USA) .............................................................................................................................................. 2689

Superior Cytotoxicity of Hydrophobic Gold Carboxylato Complexes Over Hydrophobic Silver Carboxylates. E.H.G. LANGNER, J.C. SWARTS, A. TUCHSCHERER, H. LANG, G.K. JOONE, C.E.J. VAN RENSBURG (Bloemfontein; Pretoria, Republic of South Africa; Chemnitz, Germany) .............................................................................................................................................. 2697


Cytotoxic Effects of N’-Formyl-2-(5-nitrothiophen-2-yl) benzothiazole-6-carboxydrazide in Human Breast Tumor Cells by Induction of Oxidative Stress. J.R. RODRIGUEZ, J. CHARRIS, J. CAMACHO, A. BARAZARTE, N. GAMBOA, F. ANTUNES (Lisbon, Portugal; Caracas, Venezuela) .............................................................................................................................................. 2721

Contents continued on the preceding page
* Review: PI3 Kinase Inhibitors in the Clinic: An Update. J.-E. KURTZ, I. RAY-COQUARD (Strasbourg; Lyon, France) ........................................... 2463

* Review: Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders. M. ROGOSNITZKY, R. DANKS, E. KARDASH (Telz Stone, Israel; Steep, UK) ........................................... 2471

siRNA-Mediated Down-regulation of Ceramide Synthase 1 Leads to Apoptotic Resistance in Human Head and Neck Squamous Carcinoma Cells After Photodynamic Therapy. D. SEPAROVIC, P. BREEN, N. JOSEPH, J. BIELAWSKI, J.S. PIERCE, E. VAN BUREN, T.I. GUDZ (Detroit, MI; Charleston, SC, USA) ........................................... 2479

* Review: Novel Radiosensitizing Anticancer Therapeutics. A.G. LINKOUS, E.M. YAZLOVITSKAYA (Bethesda, MD; Nashville, TN, USA) ........................................... 2487

Determination of the Optimal Route of Administration of Salmonella typhimurium A1-R to Target Breast Cancer in Nude Mice. Y. ZHANG, Y. TOME, A. SUETSUGU, L. ZHANG, N. ZHANG, R.M. HOFFMAN, M. ZHAO (San Diego, CA, USA; Okinawa; Gifu, Japan) ........................................... 2501

Real-time Imaging of Apoptosis Induction of Human Breast Cancer Cells by the Traditional Chinese Medicinal Herb Tubeimu. M. HU, M. ZHAO, C. AN, M. YANG, Q. LI, Y. ZHANG, A. SUETSUGU, Y. TOME, S. YANO, Y. FU, R.M. HOFFMAN, K. HU (Beijing, PR China; San Diego, CA, USA; Gifu; Okinawa; Okayama, Japan) ........................................... 2509

* Review: New Anticancer Agents: Hormones Made within the Heart. D.L. VESELY (Tampa, FL, USA) ........................................... 2515

Anti-breast Cancer Effects of Histone Deacetylase Inhibitors and Calpain Inhibitor. M.A. MATAGA, S. ROSENTHAL, S. HEERBOTH, A. DEVALAPALLI, S. KOKOLUS, L.R. EVANS, M. LONGACRE, G. HOUSMAN, S. SARKAR (Boston, MA, USA) ........................................... 2523

The Role of PI3K/mTOR Inhibition in Combination with Sorafenib in Hepatocellular Carcinoma Treatment. R. GEDALY, P. ANGULO, C. CHEN, K. TOWNSEND CREASY, B.T. SPEAR, J. HUNDLEY, M.F. DAILY, M. SHAH, B.M. EVERS (Lexington, KY, USA) ........................................... 2531

Impact of Yangzheng Xiaoji on the Adhesion and Migration of Human Cancer Cells: The Role of the AKT Signalling Pathway. L. YE, K. JI, N. FREWER, J. JI, W.G JIANG (Cardiff, UK; Beijing, PR China) ........................................... 2537

Preventive Effect of Traditional Japanese Medicine on Neurotoxicity of FOLFOX for Metastatic Colorectal Cancer: A Multicenter Retrospective Study. A. HOSOKAWA, K. OGAWA, T. ANDO, N. SUZUKI, A. UEDA, S. KAJIURA, Y. KOYASHI, Y. TSUKIOKA, N. HIRIKA, K. YABUSHITA, J. FUKUOKA, T. SUGIYAMA (Toyama; Nagaoka; Takaoka, Japan) ........................................... 2545


Highly Efficient Cationic Ethylphosphatidylcholine siRNA Carrier for GFP Suppression in Modified Breast Cancer Cells. B. TENCHOV, Y. SUGIMOTO, R. KOYNOVA, R.W. BRUEGGE MEIER, R.J. LEE (Columbus, OH, USA) ........................................... 2563

* Review: Death by Design: Where Curcumin Sensitizes Drug-resistant Tumours. S. SAHA, A. ADHIKARY, P. BHATTACHARYYA, T. DAS, G. SA (Kolkata, India) ........................................... 2567

* Review: A Significant Role of Lipogenic Enzymes in Colorectal Cancer. M. NOTARNICOLA, C. MESSA, M.G. CARUSO (Bari, Italy) ........................................... 2585

Contents continued on the preceding page